‘Eko’ -Digital Stethoscope
Eko has developed innovative digital stethoscopes that integrate with digital technology to enhance the capabilities of traditional stethoscopes. Digital stethoscopes comes with features such as electronic auscultation, recording capabilities, and the ability to transmit and analyze heart and lung sounds using software.
This will assist clinicians in their evaluation of heart failure (HF), valvular heart disease (VHD), and atrial fibrillation (AFib), ultimately serving as an AI-enabled clinical decision support tool for echocardiogram referrals.
The exam uses an Eko digital stethoscope and app powered by the company’s AI. When Eko’s AI detects possible signs of cardiac disease, the GP can rapidly initiate further tests and potentially life-saving treatments. The current gold standard to detect heart failure is a blood test (NT-proBNP) that when ordered alone, initiates a long pathway that often fails to achieve early diagnosis and treatment in those who need it most.
Structural Murmur Detection platform allows –
Detection Sensitivity, Doubled
With over 1M heart sounds analyzed to date, our advanced machine learning algorithms are clinically validated at 90% sensitivity — double that of conventional practice.
Advanced Murmur Classification
Our novel suite of algorithms goes beyond identification. It identifies and characterizes heart sounds, distinguishing between innocent or absent, structural systolic, and diastolic murmurs.
SENSORA™ Includes:
Digital Stethoscope
3M™ Littmann® CORE Digital Stethoscope
AI Murmur Detection
Point-of-Care Application
Care Pathway Analytics
Centralized Data Accessibility
How SENSORA™ Works:
Eko’s AI-enabled technology pairs a digital stethoscope with electrocardiogram (ECG) to advanced machine learning algorithms that analyze ECG and heart sound data. TRICORDER utilizes clinically validated algorithms that detect reduced left ventricular ejection fraction (HFrEF) indicative of heart failure, structural murmurs indicative of valvular heart disease, and atrial fibrillation. The algorithms will empower clinicians to make more confident decisions for their patients’ heart health. Eko’s HFrEF algorithm has been independently validated to achieve a detection sensitivity and specificity approaching 80%.Eko’s structural murmur algorithm was validated in a real-world evidence study presented at the 2023 American Heart Association Scientific Sessions, which found that the algorithm more than doubled the detection of valvular heart disease compared to the standard method by primary care professionals, 94.1% vs. 41.2%.Eko’s atrial fibrillation detection algorithm has been clinically validated to perform at 100% sensitivity and 96.2% specificity.
Eko’s AI-enabled technology is commercially available in the U.S. and marketed to health systems as SENSORA™. The company’s algorithm for HFrEF detection is undergoing U.S. FDA review for 510(k) clearance with the intent to market under SENSORA™ once 510(k) is obtained. U.S.-based health systems interested in learning more about SENSORA™
visit ekosensora.com.